Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1997-05-23
2003-06-24
Fredman, Jeffrey (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S005000, C435S091100, C435S091200, C436S501000, C536S022100, C536S023100, C536S024300, C536S024500
Reexamination Certificate
active
06582902
ABSTRACT:
This invention was made with government support under a grant from the National Institutes of Health. The government has certain rights to this invention.
FIELD OF THE INVENTION
This invention relates to methods of making epitopes and nucleic acids embodying the epitopes so made.
BACKGROUND OF THE INVENTION
It is desireable to be able to probe and dissect the precise sites of antigen-antibody interaction. It is also desireable to find novel ways to detect antibodies and to inhibit specific antibody-antigen interactions. Furthermore, methods are needed that allow one to purify a monospecific antibody from a polyclonal serum without having to first purify the antigen.
It has not heretofore been possible to produce distinct and generally useful epitopes which react with a given antibody except in the case of epitope libraries. These peptide libraries depend upon expression of a random set of epitopes within the context of a larger protein. See, e.g., Scott et al.,
Science
249, 386 (1990); Cwirla et al.,
Proc. Natl. Acad. Sci. USA
87, 6378 (1990). This approach is restricted because it offers only proteinaceous ligands and is potentially compromised in contexts other than the fusion protein. In addition, “combinatorial peptide libraries” have been described which apply sequential positional determinations. See Houghten et al.,
Nature
454, 84 (1991). This procedure requires evaluation of the selected ligand at each step which, in turn, requires an exponential effort to define and select a specific epitope. Further, methods for screening degenerate pools of peptide sequences have been used which are not limited by proteinaceous context but are limited for logistical reasons (e.g., sophisticated synthesis and detection instruments are required). See Fodor et al.,
Science
251, 767 (1991); Geysen et al.,
Proc. Natl. Acad. Sci. USA
81, 3998 (1984).
S. Deutscher and J. Keene,
Proc. Natl. Acad. Sci. USA
85, 3299 (1988) describe the selection and amplification of a nucleic acid ligand on U1 RNA from a randomized pool of nucleic acids (see also J. Wilusz and J. Keene,
J. Biol. Chem.
261, 5467 (1986)). L. Gold and C. Tuerk,
Nucleic Acid Ligands
, PCT Appln. Publn No. WO 91/19813 (Dec. 26, 1991), describe the “evolution” of nucleic acid ligands and nucleic acid compounds refered to as “nucleic acid antibodies” (see also C. Tuerk and L. Gold,
Science
249, 505-510 (1990)). A. Ellington and J. Szostak,
Nature
346, 818-822 (1990), describe the binding of RNA molecules to organic dyes. D. Tsai et al.,
Nucleic Acids Research
19, 4931-4936 (1991), describe the binding of the U1-snRNP-A protein to specific RNA sequences in a degenerate pool of transcripts. D. Bartel et al.,
Cell
67, 529-563 (1991), describe the binding of the Rev protein of HIV-1 to a nucleic acid pool.
There has not heretofore been described a method by which an antibody can be employed to derive a nonproteinaceous mimetic ligand that binds to the same site on the antibody to which the original antigen bound.
SUMMARY OF THE INVENTION
A first aspect of the present invention is a method of generating a nucleic acid molecule which is immunologically cross-reactive with an immunogen, which immunogen is not a nucleic acid (e.g., a peptide). The method comprises combining an antigen binding protein which binds the immunogen (e.g., an antibody, a T cell receptor) with a degenerate pool of nucleic acid species, and then recovering a nucleic acid species bound by said binding protein from the degenerate pool.
A second aspect of the present invention is an isolated nucleic acid which inhibits complex formation between an antigen binding protein and an immunogen, which immunogen is not a nucleic acid. In one embodiment, the nucleic acid inhibits complex formation between a self peptide autoantigen and an antigen binding protein.
The foregoing and other objects and aspects of the present invention are explained in detail in the drawings herein and the specification set forth below.
REFERENCES:
patent: 5270163 (1993-12-01), Gold et al.
patent: 8600991 (1986-02-01), None
patent: WO91/19813 (1991-12-01), None
Bock et al, (Feb. 1992), “Selection of single-stranded DNA molecules that bind and inhibit human thrombin”, Nature 355:564-566.*
Naparstek et al, (1990), “Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-Ipr/Ipr mice by heparin”, Arth. Rheum. 33(10):1554-1559.*
Reichlin et al, (1994), “Lupus autoantibodies to native DNA cross-react with the A and D SnRNP polypeptides”, J. Clin. Invest. 93:443-449.*
Wright et al, (Aug. 1991), “Cyclic amplification and selection of targets (CASTing) for the myogenin consencus binding site”, Mol. Cell. Biol. 11(8):4104-4110.*
D. P. Bartel et al.,Cell 67,529-536 (1991).
D.E. Tsai et al,Nucleic Acids Research, 19,4931-4936 (1991).
A.D. Ellington et al.,Nature 346,818-822 (1990).
C. Turek et al.,Science 249,505-510 (1990).
S. Deutscher et al.,Proc. Natl. Acad. Sci. 85,3299-3303 (1988).
J. Wilusz et al.,The Journal of Biological Chemistry 261,5467-5472 (1986).
D.E. Tsai, et al.,In vitro selection of anRNAepitope immunologically cross-reactive with a peptide, Proc. Natl. Acad, Sci 89,pp 8864-8868 (Oct. 1992).
D.E. Tsai & J.D. Keene,In Vitro Selection ofRNAEpitopes Using Autoimmune Patient Serum1, The Journal of Immunology, 150,pp 1137-1145 (Feb. 1993).
S.M. Edgington,Shape Space, Bio/Technology, 11pp 285-289 (1993).
D.J. Kenan,Exploring Molecular Diversity With Combinatorial Shape Libraries, Trends in Biochemical Sciences/19,pp 57-64 (1994).
Keene Jack D.
Kenan Daniel J.
Tsai Donald E.
Fredman Jeffrey
Myers Bigel & Sibley Sajovec, PA
LandOfFree
Method for deriving epitopes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for deriving epitopes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for deriving epitopes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3135847